Mabwell (Shanghai) Bioscience Co., Ltd. (SHA:688062)
31.17
-2.93 (-8.59%)
Aug 21, 2026, 3:00 PM CST
SHA:688062 Revenue
Mabwell (Shanghai) Bioscience had revenue of 127.60M CNY in the quarter ending March 31, 2026, with 184.89% growth. This brings the company's revenue in the last twelve months to 745.32M, up 321.05% year-over-year. In the year 2025, Mabwell (Shanghai) Bioscience had annual revenue of 662.52M with 231.62% growth.
Revenue (ttm)
745.32M
Revenue Growth
+321.05%
P/S Ratio
17.85
Revenue / Employee
562.51K
Employees
1,325
Market Cap
13.30B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 662.52M | 462.73M | 231.62% |
| Dec 31, 2024 | 199.78M | 71.95M | 56.28% |
| Dec 31, 2023 | 127.84M | 100.11M | 361.03% |
| Dec 31, 2022 | 27.73M | 11.50M | 70.88% |
| Dec 31, 2021 | 16.23M | 10.92M | 206.03% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Anhui Anke Biotechnology (Group) | 2.56B |
| Jinyu Bio-technology | 1.53B |
| Nanjing Vazyme Biotech | 1.41B |
| BrightGene Bio-Medical Technology | 1.30B |
| Shanghai Medicilon | 1.26B |
| Hualan Biological Vaccine | 1.20B |
| Acrobiosystems | 887.21M |
| GemPharmatech | 878.13M |